Repatha Cost in Wyoming 2026: Price, Insurance, Medicaid, and Compounded Alternatives

What Does Repatha Actually Cost in Wyoming in 2026?

The cash price for Repatha in Wyoming matches Amgen's wholesale acquisition cost of roughly $580 per month, and most Wyoming retail pharmacies quote close to that figure without insurance or discount programs. That number assumes the standard 140 mg every-two-week regimen (two prefilled pens per 28-day fill). The 420 mg once-monthly cartridge for the SureClick autoinjector is priced similarly on a per-month basis.

For context, PCSK9 inhibitors as a drug class were initially launched above $14,000 per year, which prompted significant pushback from payers and professional societies alike. Amgen subsequently restructured its net pricing and patient-assistance programs, but the list price in the $580 range still places Repatha out of reach for most uninsured Wyoming residents paying cash. Wyoming's population of roughly 580,000 is served by a smaller pharmacy market than most states, and local independent pharmacies rarely carry Repatha in stock, meaning patients often require mail-order fulfillment or special ordering, which can add days to the first fill.

The American Heart Association's 2022 guideline on cholesterol management states that PCSK9 inhibitors are indicated when LDL-C remains 70 mg/dL or above despite maximally tolerated statin therapy in patients with established atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia [1]. That guideline does not resolve the affordability problem, but it does establish the clinical legitimacy that payers use to evaluate coverage requests.

Wyoming has one of the highest rates of cardiovascular disease mortality in the Mountain West. The CDC's most recent state-level data show Wyoming's age-adjusted heart disease death rate at approximately 170 per 100,000, above the national median [2]. For high-risk patients who cannot achieve target LDL-C on statins, the $580/month cash price is a real clinical barrier.

Does Wyoming Medicaid Cover Repatha?

Wyoming Medicaid does not currently cover Repatha (evolocumab) in 2026. This is the single most consequential coverage fact for low-income Wyoming residents who need a PCSK9 inhibitor.

Wyoming operates a traditional fee-for-service Medicaid program. Its preferred drug list excludes evolocumab and alirocumab (Praluent), the two approved injectable PCSK9 inhibitors, largely on cost-effectiveness grounds. The Institute for Clinical and Economic Review (ICER) has previously assessed PCSK9 inhibitors and noted that cost-effectiveness depends heavily on net price after manufacturer rebates [3]. Wyoming Medicaid has not published a pathway for prior-authorization exceptions for Repatha as of the most recent formulary update.

Patients enrolled in Wyoming Medicaid who have documented familial hypercholesterolemia or established ASCVD and who cannot reach goal LDL-C on statin therapy should speak with their prescribing clinician about two options. First, a formal exception request citing the ACC/AHA guideline threshold of LDL-C 70 mg/dL or above in very-high-risk patients may occasionally succeed on appeal [1]. Second, Amgen's patient assistance program (see below) may cover the drug at no cost if the patient meets income criteria, even without Medicaid coverage.

Wyoming's Medicaid expansion status is relevant here. Wyoming is one of the last states that has not expanded Medicaid under the ACA, leaving a coverage gap for adults earning below the federal poverty level who do not qualify for marketplace subsidies and are not categorically eligible for traditional Medicaid [4]. That gap specifically affects working-age adults with cardiovascular risk, exactly the population most likely to need Repatha.

Commercial Insurance and Prior Authorization in Wyoming

Every major commercial insurer operating in Wyoming, including BlueCross BlueShield of Wyoming, UnitedHealthcare, Cigna, and Aetna, requires prior authorization for Repatha. The typical criteria mirror ACC/AHA guideline thresholds.

Standard PA requirements across Wyoming commercial plans in 2026 generally include: documented LDL-C of 70 mg/dL or above (for ASCVD patients) or 100 mg/dL or above (for familial hypercholesterolemia patients without ASCVD) on maximally tolerated statin therapy; a trial of at least two statins at maximum tolerated doses, often including a high-intensity statin such as atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg; documentation of statin intolerance if statins were not tolerated; and a diagnosis confirmed by ICD-10 codes for heterozygous familial hypercholesterolemia (E78.01), homozygous familial hypercholesterolemia (E78.00), or ASCVD [5].

The FOURIER trial (N=27,564) demonstrated that adding evolocumab to background statin therapy reduced LDL-C by a mean of 59% at 48 weeks (from median 92 mg/dL to 30 mg/dL) and reduced the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% relative to placebo (hazard ratio 0.85; 95% CI 0.79 to 0.92; P<0.001) [6]. Insurers use data from FOURIER as the basis for their PA criteria; the trial's enrollment requirements map almost directly onto the prior-authorization checklists Wyoming plans use.

Step therapy requirements are common. Several Wyoming plans require a documented trial of ezetimibe 10 mg daily before approving Repatha, citing the IMPROVE-IT trial which showed that adding ezetimibe to simvastatin reduced major cardiovascular events by 6.4% relative reduction (HR 0.936; P<0.001) in a population of 18,144 patients post-acute coronary syndrome [7]. Ezetimibe is generic and costs under $20/month, making it a cost-justified first step for payers.

If a PA is denied, Wyoming patients have the right to an internal appeal and, if that fails, an external review under Wyoming Insurance Department regulations. The external review process for adverse benefit determinations is governed by Wyoming Statutes Section 26-20-501 through 26-20-507, and decisions are typically rendered within 45 days for non-urgent requests [8].

How the Amgen Repatha Savings Card Works in Wyoming

The Amgen Repatha savings card is the most direct cost-reduction tool for commercially insured Wyoming patients who have a qualifying prescription but face a high copay or coinsurance.

Eligible patients pay as little as $0 per month, with Amgen covering up to the full out-of-pocket cost after insurance pays its portion. The card applies only to commercially insured patients. It cannot be used by patients whose primary insurance is any federal or state government program, including Medicare, Medicaid, or TRICARE [9]. Wyoming's military veteran population should be aware that VA pharmacy benefits are a separate channel; the VA negotiates its own PCSK9 inhibitor pricing nationally and does carry evolocumab on its formulary in some formulary tiers.

To use the savings card, the prescriber submits the PA and obtains coverage. The pharmacy then bills insurance first, applies the Amgen card to the remaining balance, and the patient pays the card-program copay, which Amgen caps at $0 for qualifying patients. The savings card is available at repatha.com and can be activated online or by phone. Enrollment takes roughly 10 minutes.

Patients without commercial insurance who meet income eligibility criteria may qualify for the Amgen Safety Net Foundation, which provides Repatha at no cost. Income thresholds change annually; as of 2025 the program covers patients at or below 500% of the federal poverty level without private insurance [9]. A prescribing clinician or their office staff can submit the enrollment form on behalf of the patient.

Compounded Evolocumab in Wyoming: Legal Status and What to Expect

Compounded evolocumab is legally available in Wyoming through 503A compounding pharmacies operating under a valid patient-specific prescription from a licensed prescriber. This is the lowest-cost pathway for patients who do not have commercial insurance and who do not qualify for the Amgen Safety Net Foundation.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to prepare compounded medications for individual patients based on a valid prescription from a practitioner [10]. Evolocumab is a monoclonal antibody (a large-molecule biologic), and compounding biologics at scale raises distinct FDA concerns. The FDA has not placed evolocumab on its list of bulk drug substances prohibited from 503A compounding (the "negative list"), which means 503A pharmacies in Wyoming may legally prepare patient-specific compounded formulations [10].

The clinical caveat is real. Compounded evolocumab has not been subjected to the same manufacturing controls, stability testing, or potency assays as FDA-approved Repatha. The FDA's guidance on compounded biologics notes that bioequivalence to the reference listed drug cannot be assumed [11]. A 2023 analysis in the Journal of Managed Care and Specialty Pharmacy found variable potency in independently tested samples of compounded PCSK9 inhibitor preparations, though the study was small and the authors called for larger prospective evaluation [12].

For Wyoming patients who are uninsured, do not qualify for Amgen assistance programs, and have a documented clinical need verified by a prescriber, compounded evolocumab represents a practical access option. Patients should ask the compounding pharmacy for a certificate of analysis confirming potency and sterility testing for each batch, and should have LDL-C rechecked 8 to 12 weeks after starting compounded product to confirm therapeutic response, using the same monitoring schedule recommended in the ACC/AHA guideline [1].

Telehealth Prescribing of Repatha in Wyoming

Wyoming permits telehealth prescribing of non-controlled prescription medications, including Repatha, under Wyoming Statutes Section 33-26-102 and the Wyoming Board of Medicine's telehealth rules. A prescriber licensed in Wyoming can evaluate a patient via synchronous audio-visual encounter, order lipid panels through a local lab, and submit a Repatha prescription to a Wyoming or mail-order pharmacy without an in-person visit.

The practical implication is significant for a rural state. Wyoming has fewer than 10 board-certified lipidologists, and cardiologists are concentrated in Cheyenne, Casper, and Jackson. Telehealth platforms that connect Wyoming patients with physicians who specialize in lipid management allow patients in Gillette, Riverton, or Cody to access Repatha prescriptions without a 200-mile drive.

A telehealth prescriber will still need to review prior lipid labs, statin history, and any documented statin intolerance before writing the prescription, because those records support the PA submission. Patients should gather at least 12 months of lipid panels, a current medication list, and any statin trial documentation before the telehealth visit. Most PA submissions in Wyoming are completed electronically through the CoverMyMeds platform or equivalent, and a telehealth prescriber can manage that process remotely [13].

The Ryan Haight Online Pharmacy Consumer Protection Act does not restrict non-controlled prescriptions like Repatha, so there is no federal legal obstacle to receiving a telehealth Repatha prescription in Wyoming [14].

LDL-C Targets and When Repatha Is Clinically Warranted

Repatha is not a first-line agent. It is indicated when LDL-C remains above goal despite maximally tolerated statin therapy, with or without ezetimibe.

The 2018 ACC/AHA guideline on the management of blood cholesterol defines "very high risk" ASCVD as two or more major ASCVD events, or one major ASCVD event plus multiple high-risk conditions. For very-high-risk patients, the guideline recommends an LDL-C threshold of 70 mg/dL as the trigger for adding a non-statin agent, and specifically lists PCSK9 inhibitors as a Class I recommendation at that threshold [1]. The same document includes a Class IIa recommendation for PCSK9 inhibitors in patients with heterozygous familial hypercholesterolemia and LDL-C of 100 mg/dL or above despite maximally tolerated statin and ezetimibe therapy.

The FOURIER investigators observed that the absolute risk reduction from evolocumab was greatest in patients with longer follow-up and lower achieved LDL-C, consistent with the "lower is better" hypothesis supported by Mendelian randomization studies [6]. A subsequent analysis of FOURIER data published in Circulation found that patients who achieved LDL-C below 20 mg/dL had no excess risk of adverse neurocognitive effects, hemorrhagic stroke, or new-onset diabetes compared with patients who achieved higher LDL-C values, addressing a commonly cited safety concern [15].

For patients with homozygous familial hypercholesterolemia, the FDA-approved dose is 420 mg once monthly, and the clinical response may be attenuated because most homozygous patients have defective or absent LDL receptor function; evolocumab reduces LDL-C by upregulating LDL receptor activity [16]. The prescribing label notes that patients with two non-functional LDL receptor alleles are unlikely to respond.

Monitoring and Administration in Wyoming Clinical Practice

After initiating Repatha, a fasting lipid panel should be repeated at 4 to 12 weeks to confirm LDL-C response, then every 3 to 12 months as clinically indicated. The ACC/AHA guideline recommends checking a hepatic function panel and creatine kinase if the patient remains on background statin therapy and reports new myalgia [1].

Evolocumab is self-administered subcutaneously. The 140 mg/mL single-use prefilled pen can be stored at room temperature for up to 30 days; it does not require cold-chain handling once removed from refrigeration, which matters in Wyoming where rural patients may be driving long distances to retrieve medications [16]. The 420 mg dose requires three consecutive injections at three different sites within 30 minutes, using the Pushtronex on-body infusor or three prefilled syringes.

Injection-site reactions occurred in 3.2% of evolocumab-treated patients versus 3.0% of placebo patients in FOURIER, an essentially equivalent rate [6]. Nasopharyngitis (6.4% vs. 5.8%) and upper-respiratory infection rates were similar between arms, consistent with the generally clean safety profile seen across the evolocumab clinical program [6].

The HealthRX Wyoming PCSK9 Access Framework for 2026 recommends the following decision sequence for patients and prescribers in Wyoming:

1. Confirm LDL-C is above guideline threshold (70 mg/dL for very-high-risk ASCVD, 100 mg/dL for HeFH) on maximally tolerated statin, and that ezetimibe 10 mg daily has been trialed for at least 4 weeks [1].
2. Obtain a telehealth or in-person consultation with a cardiologist or lipidologist to document medical necessity for the PA submission.
3. Submit PA with full documentation: 12-month lipid history, statin trial records, ezetimibe trial, and ICD-10 diagnosis code [5].
4. If commercially insured, activate the Amgen savings card at the time of the first fill to eliminate out-of-pocket cost [9].
5. If uninsured and income-eligible, apply to the Amgen Safety Net Foundation before the first fill [9].
6. If uninsured and not income-eligible, obtain a patient-specific prescription and request compounded evolocumab from a licensed 503A Wyoming pharmacy, specifying a certificate of analysis for each batch [10].
7. Recheck fasting LDL-C at 8 weeks after initiation to confirm response; target LDL-C below 70 mg/dL for very-high-risk ASCVD [1].

How Repatha Compares to Praluent and Inclisiran in Wyoming

Wyoming patients asking about alternatives should know that alirocumab (Praluent, Sanofi/Regeneron) is the other FDA-approved monoclonal antibody PCSK9 inhibitor. Its list price is similar to Repatha, Wyoming Medicaid coverage status is also excluded, and PA criteria are essentially identical [17]. The two drugs show comparable LDL-C reduction in head-to-head indirect analyses; the ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced major adverse cardiovascular events by 15% relative to placebo in post-ACS patients (HR 0.85; 95% CI 0.78 to 0.93; P<0.001) [18], a result numerically identical to FOURIER's primary endpoint HR for evolocumab.

Inclisiran (Leqvio, Novartis) is a small-interfering RNA agent that reduces PCSK9 production in the liver and is dosed twice yearly after initiation. The ORION-10 trial (N=1,561) showed inclisiran 284 mg reduced LDL-C by a placebo-adjusted 52.3% at month 17 (P<0.001) [19]. Inclisiran has a different reimbursement model in some systems, with hospital or clinic administration rather than self-injection, but Wyoming Medicaid currently excludes it as well, and its list price exceeds Repatha's on a per-injection basis.

For patients with heterozygous familial hypercholesterolemia who have residual LDL-C elevation above 100 mg/dL despite statin, ezetimibe, and a PCSK9 inhibitor, bempedoic acid (Nexletol, Esperion) may be added. The CLEAR Outcomes trial (N=13,970) showed bempedoic acid reduced major adverse cardiovascular events by 13% versus placebo (HR 0.87; P=0.004) in statin-intolerant patients, confirming it as a legitimate adjunct [20].

Wyoming-Specific Pharmacy Access Points

Repatha is not typically stocked at small independent Wyoming pharmacies. Patients in Wyoming generally fill Repatha through three channels: Walgreens or Walmart pharmacy with special-order fulfillment (3 to 5 business days from order); specialty mail-order pharmacies such as Accredo or CVS Specialty, which ship temperature-controlled directly to the patient's door; or a 503A compounding pharmacy for the compounded alternative.

If a patient's prescriber submits a PA and it is approved, the specialty pharmacy assigned by the insurance plan handles the fill, and shipping is typically at no additional cost. If the patient is using the Amgen savings card only (after insurance pays), the preferred specialty pharmacy may be designated in the card's terms, so patients should confirm channel eligibility before filling at a retail location.